NEW YORK , Nov. 5, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 3.69% during the forecast period. Rising global burden of diabetes is driving market growth, with a trend towards increasing growth opportunities in emerging markets.
However, stringent regulatory guidelines poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc.
, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co.
Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd.
, Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc.
, Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co.
Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc.
, and Neurogastrx Inc.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth Vendors in the gastrointestinal drugs market are expanding their businesses in emerging economies to tap into the growing number of undiagnosed and untreated patients with gastrointestinal disorders. For instance, the incidence and prevalence of chronic gastrointestinal disorders in Asia , particularly in China a.
